Skip to main content

Advertisement

SpringerLink
Log in

Denosumab in the treatment of glucocorticoid-induced osteoporosis

  • Review
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Glucocorticoid therapy is the number one cause of secondary osteoporosis particularly effecting young individuals. Possessing an increased risk for fractures, glucocorticoid-induced osteoporosis might interfere with patients’ well-being and quality of life. Therefore, proper treatment of bone loss and prevention from fractures are of great importance. There are a limited number of therapeutic and preventative options for glucocorticoid-induced osteoporosis. Denosumab, with its high anti-resorptive potential, has been studied several times among patients on glucocorticoid therapy. However, a comprehensive look analysing the current data is lacking. Thus, the objective of the current article is to evaluate the current evidence on the efficacy, as well as the safety profile of denosumab in glucocorticoid-induced osteoporosis. Pubmed/MEDLINE, Scopus and Web of Science databases were searched for the terms denosumab, glucocorticoid-induced osteoporosis, steroid-induced osteoporosis, glucocorticoids and osteoporosis. Relevant data regarding the efficacy and safety of denosumab among patients with glucocorticoid-induced osteoporosis was analysed. Denosumab contributes to increased bone mineral density and decreased bone-turnover marker levels among glucocorticoid users. It is an effective therapeutic option with a favourable safety profile in glucocorticoid-induced osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Saag KG, Buttgereit F (2019) Systemic glucocorticoids in rheumatology. In: Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 7th edn. Elsevier, Philadelphia, pp 488–498

    Google Scholar 

  2. Curtis J, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V et al (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55:420–426

    Article  Google Scholar 

  3. Hsu E, Nanes M (2017) Advances in treatment of glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes Obes 24:411–417

    Article  CAS  Google Scholar 

  4. Coskun Benlidayi I, Basaran S, Evlice A, Erdem M, Demirkiran M (2015) Prevalence and risk factors of low bone mineral density in patients with multiple sclerosis. Acta Clin Belg 70:188–192

    Article  CAS  Google Scholar 

  5. Pereira RM, Carvalho JF, Canalis E (2010) Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics (Sao Paulo) 65:1197–1205

    Article  Google Scholar 

  6. Rossini M, Viapiana O, Vitiello M, Malavolta N, La Montagna G, Maddali Bongi S et al (2017) Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Reumatismo 69:30–39

    Article  CAS  Google Scholar 

  7. Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD et al (2016) Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 27:1709–1718

    Article  CAS  Google Scholar 

  8. Kim D, Cho SK, Park B, Jang EJ, Bae SC, Sung YK (2018) Glucocorticoids are associated with an increased risk for vertebral fracture in patients with rheumatoid arthritis. J Rheumatol 45:612–620

    Article  Google Scholar 

  9. Nazrun AS, Tzar MN, Mokhtar SA, Mohamed IN (2014) A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag 10:937–948

    PubMed  PubMed Central  Google Scholar 

  10. González-Macías J, Del Pino-Montes J, Olmos JM, Nogués X, en nombre de la Comisión de Redacción de las Guías de Osteoporosis de la SEIOMM (2015) Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014). Rev Clin Esp 215:515–526

    Article  Google Scholar 

  11. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE et al (2017) 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 69:1521–1537

    Article  Google Scholar 

  12. Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO) et al (2014) 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Jt Bone Spine 81:493–501

    Article  Google Scholar 

  13. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Scientific Advisory Council of Osteoporosis Canada et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873

    Article  Google Scholar 

  14. Chitre M, Shechter D, Grauer A (2011) Denosumab for treatment of postmenopausal osteoporosis. Am J Health Syst Pharm 68:1409–1418

    Article  CAS  Google Scholar 

  15. Gu HF, Gu LJ, Wu Y, Zhao XH, Zhang Q, Xu ZR et al (2015) Efficacy and safety of denosumab in postmenopausal women with osteoporosis: a meta-analysis. Medicine (Baltimore) 94:e1674

    Article  CAS  Google Scholar 

  16. United States Food and Drug Administration (2018) https://www.accessdata.fda.gov/drugsatfda_docs /label/2018/125320s186lbl.pdf. Accessed 3 Jul 2018

  17. Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417

    Article  Google Scholar 

  18. Compston J (2018) Glucocorticoid-induced osteoporosis: an update. Endocrine. https://doi.org/10.1007/s12020-018-1588-2

    Article  PubMed  PubMed Central  Google Scholar 

  19. Jacobs JWG, Bijlsma JWJ (2017) Glucocorticoid therapy. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’dell JR (eds) Kelley and Firestein’s textbook of rheumatology, 10th edn. Elsevier, Philedelphia, pp 932–957

    Chapter  Google Scholar 

  20. Lau AN, Sambrook PN, Adachi JD (2015) Glucocorticoid-induced osteoporosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 6th edn. Elsevier, Philadelphia, pp 1674–1678

    Google Scholar 

  21. Rossini M, Gatti D, Adami S (2013) Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93:121–132

    Article  CAS  Google Scholar 

  22. Deal CL, Abelson AG (2019) Management of osteoporosis. In: Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 7th edn. Elsevier, Philadelphia, pp 1671–1682

    Google Scholar 

  23. Kim K, Kim JH, Kim I, Lee J, Seong S, Park YW et al (2015) MicroRNA-26a regulates RANKL-induced osteoclast formation. Mol Cells 38:75–80

    CAS  PubMed  Google Scholar 

  24. Akbar MA, Nardo D, Chen MJ, Elshikha AS, Ahamed R, Elsayed EM et al (2017) Alpha-1 antitrypsin inhibits RANKL-induced osteoclast formation and functions. Mol Med 21:23

    Google Scholar 

  25. Scott LJ (2014) Denosumab: a review of its use in postmenopausal women with osteoporosis. Drugs Aging 31:555–576

    Article  CAS  Google Scholar 

  26. Mok CC, Ho LY, Ma KM (2015) Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone 75:222–228

    Article  CAS  Google Scholar 

  27. Matsuno H (2016) Assessment of distal radius bone mineral density in osteoporosis patients receiving denosumab, including those with rheumatoid arthritis and those receiving oral glucocorticoids. Drugs R D 16:347–353

    Article  Google Scholar 

  28. Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T et al (2018) The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial. PLoS One 13:e0193846

    Article  Google Scholar 

  29. Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R et al (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445–454

    Article  CAS  Google Scholar 

  30. Petranova T, Sheytanov I, Monov S, Nestorova R, Rashkov R (2014) Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnol Biotechnol Equip 28:1127–1137

    Article  Google Scholar 

  31. Sawamura M, Komatsuda A, Togashi M, Wakui H, Takahashi N (2017) Effects of denosumab on bone metabolic markers and bone mineral density in patients treated with glucocorticoids. Intern Med 56:631–636

    Article  CAS  Google Scholar 

  32. Ishiguro S, Ito K, Nakagawa S, Hataji O, Sudo A (2017) The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease. Arch Osteoporos 12:44

    Article  Google Scholar 

  33. Suzuki T, Nakamura Y, Kato H (2018) Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. Mod Rheumatol 22:1–5

    Google Scholar 

  34. Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, Denosumab RA Study Group et al (2010) Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 69:872–875

    Article  CAS  Google Scholar 

  35. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513–523

    Article  CAS  Google Scholar 

  36. Deeks ED (2018) Denosumab: a review in postmenopausal osteoporosis. Drugs Aging 35:163–173

    Article  CAS  Google Scholar 

  37. Beaudoin C, Jean S, Bessette L, Ste-Marie LG, Moore L, Brown JP (2016) Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int 27:2835–2844

    Article  CAS  Google Scholar 

  38. Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S et al (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121:1291–1299

    Article  CAS  Google Scholar 

  39. Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A et al (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48–54

    Article  CAS  Google Scholar 

  40. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153–161

    Article  CAS  Google Scholar 

  41. Fontalis A, Kenanidis E, Prousali E, Potoupnis M, Tsiridis E (2018) Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis. Expert Opin Drug Saf 17:413–428

    Article  CAS  Google Scholar 

  42. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972–980

    Article  CAS  Google Scholar 

  43. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al FREEDOMTrial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

    Article  CAS  Google Scholar 

  44. Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471–1479

    Article  CAS  Google Scholar 

  45. Bussiere JL, Pyrah I, Boyce R, Branstetter D, Loomis M, Andrews-Cleavenger D et al (2013) Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol 42:27–40

    Article  CAS  Google Scholar 

  46. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701

    Article  CAS  Google Scholar 

  47. Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26:2773–2783

    Article  CAS  Google Scholar 

  48. Miller PD (2011) A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis 3:271–282

    Article  CAS  Google Scholar 

  49. Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L et al (2016) Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant 16:1882–1891

    Article  CAS  Google Scholar 

  50. Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B et al (2018) Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int. https://doi.org/10.1007/s00198-018-4533-6

    Article  PubMed  Google Scholar 

  51. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, National Osteoporosis Guideline Group (NOGG) et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43

    Article  CAS  Google Scholar 

  52. de Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Dramé M, Trenque T (2017) Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol 73:517–523

    Article  Google Scholar 

  53. Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA (2016) Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res 27:367–375

    Article  Google Scholar 

  54. Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA et al (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163–3170

    Article  CAS  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Cukurova University, Adana, Turkey

    Ilke Coskun Benlidayi

Authors
  1. Ilke Coskun Benlidayi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ICB contributed to the conception and design of the study; collection and interpretation of data; drafting and revising the article; and approval of the final version.

Corresponding author

Correspondence to Ilke Coskun Benlidayi.

Ethics declarations

Conflict of interest

The author declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Coskun Benlidayi, I. Denosumab in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 38, 1975–1984 (2018). https://doi.org/10.1007/s00296-018-4106-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-018-4106-1

Keywords

Search

Navigation